RxDoctor Payments Data

Jason Reynolds, MD

Urology · Elizabethtown, KYNPI 1366686693

Payments from drug & device makers

$2,765in general payments, 2019–2025

Across 82 payments — averaging $33.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$899
  • Boston Scientific$383
  • C. R. Bard, Inc. & Subsidiaries$180
  • Astellas Pharma US Inc$132
  • Urogen Pharma, Inc.$122
  • Davol Inc.$113
  • plus $936 from 28 others

What the payments were for

  • Travel & lodging$58721%
  • Food & beverage$2,07275%
  • Education$1054%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,765 in reported general payments places this provider in the 45th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$366,228
Medicare patients
705
Services billed
3,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron80$47,278
GemtesaVibegron34$17,597
Tamsulosin Hcl699$8,874
Finasteride569$5,608
Potassium Citrate ErPotassium Citrate16$2,437
Oxybutynin Chloride ErOxybutynin Chloride68$1,279
Estradiol16$970
Testosterone Cypionate32$846
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet29$713
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen194$430
Doxazosin Mesylate18$392
Cephalexin82$392
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$316
Doxycycline Hyclate31$259
Alfuzosin Hcl ErAlfuzosin Hcl14$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$132$47,27880 claims
Sumitomo Pharma America, Inc.Gemtesa$42$17,59734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 139 urology providers in Kentucky.

Other urology in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →